Corresponding Author: Michael S. Saag, MD, School of Medicine, University of Alabama at Birmingham, 845 19th St S, BBRB 256, Birmingham, AL 35294 (msaag@uabmc.edu).
Accepted for Publication: September 2, 2020.
Published Online: October 14, 2020. doi:10.1001/jama.2020.17025
Author Contributions: Dr Saag had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Saag, Gandhi, Hoy, Landovitz, Thompson, Sax, Smith, Benson, del Rio, Eron, Fätkenheuer, Günthard, Jacobsen, Volberding.
Acquisition, analysis, or interpretation of data: Saag, Hoy, Landovitz, Thompson, Sax, Smith, Benson, Buchbinder, del Rio, Fätkenheuer, Günthard, Molina, Volberding.
Drafting of the manuscript: Saag, Gandhi, Hoy, Landovitz, Thompson, Sax, Smith, Benson, del Rio, Fätkenheuer, Jacobsen, Volberding.
Critical revision of the manuscript for important intellectual content: Saag, Hoy, Landovitz, Thompson, Sax, Smith, Benson, Buchbinder, Eron, Fätkenheuer, Günthard, Molina.
Statistical analysis: Fätkenheuer.
Obtained funding: Jacobsen.
Administrative, technical, or material support: Saag, Sax, Smith, Fätkenheuer, Jacobsen, Volberding.
Supervision: Saag, Landovitz, Smith, Benson, Fätkenheuer, Molina, Jacobsen.
Conflict of Interest Disclosures: Drs Saag reported receiving grants paid to his institution from Gilead Sciences and ViiV Healthcare. Dr Gandhi reported serving on advisory boards and receiving personal fees from Gilead, Merck, and Theratechnologies. Dr Hoy reported receiving personal fees paid to her institution from Gilead Sciences, ViiV Healthcare, and Merck, Sharp & Dohme Australia. Dr Landovitz reported reported serving on advisory boards and receiving personal fees and travel reimbursement from Gilead Sciences and Merck; and receiving personal fees and travel reimbursement from Roche. Dr Thompson reported receiving research support paid to the AIDS Research Consortium of Atlanta for the conduct of clinical trials from Bristol-Myers Squibb, Cepheid Inc, Cytodyn Inc, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme, Frontier Biotechnology, and ViiV Healthcare. Dr Sax reported serving on advisory boards and receiving grants and personal fees from Gilead and ViiV; and serving on advisory boards and receiving personal fees from Janssen and Merck. Dr Smith reported receiving grants from the National Institutes of Health; and serving as a consultant and receiving personal fees from Arena Pharma, Bayer, and AIDS Healthcare Foundation; and serving on advisory boards and receiving personal fees from FluxErgy. Dr Benson reported receiving grants paid to her institution from the National Institutes of Health and Gilead; and receiving personal fees from ViiV Healthcare, GlaxoSmithKline, IDSA, and IAS-USA. Dr Buchbinder reported receiving nonfinancial support (study drug) from Gilead Sciences. Dr del Rio reported receiving grants from the National Institutes of Health. Dr Eron reported receiving grants and personal fees from ViiV Healthcare, Gilead Sciences, and Janssen; and receiving personal fees from Merck. Dr Fätkenheuer reported receiving grants and personal fees from Janssen Cilag; receiving grants and travel reimbursement from Gilead; serving on advisory boards and receiving grants from Merck Sharp & Dohme; and serving on advisory boards and receiving personal fees from ViiV Healthcare. Dr Günthard reported receiving grants from the Swiss National Science Foundation, the Swiss HIV Cohort Study, the National Institutes of Health, Gilead Sciences, the Yvonne Jacob Foundation; and serving as a consultant and receiving personal fees from Merck, Gilead Sciences, and ViiV Healthcare. Dr Molina reported serving on advisory boards and receiving personal fees from Gilead, Merck, and ViiV Healthcare. Dr Volberding reported receiving personal fees from Merck and Gilead. No other disclosures were reported.
Funding/Support: The work is sponsored and funded by the International Antiviral Society–USA (IAS-USA). IAS-USA is a mission-based, nonmembership, 501(c)(3) not-for-profit organization. No private sector or government funding was used to support the effort. Panel members are not compensated for participation in the effort.
Role of the Funder/Sponsor: The IAS-USA determined the need to update recommendations, selected the panel members, and provided administrative support and oversight. The panel designs and conducts the work; collects, manages, analyzes, and interprets the data; and prepares, reviews, and approves the manuscript.
Additional Contributions: We thank Michelle Valderama, BS (production and web manager from the IAS-USA), for assistance in managing the manuscript versions, and Kimberly R. Powell, MIS (systematic review methodologist from Emory University), for conducting the PubMed and EMBASE literature searches. Neither received additional compensation beyond their normal salaries. We dedicate this article to the memory of Timothy Ray Brown.
1.Saag
MS , Benson
CA , Gandhi
RT ,
et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society–USA panel.
JAMA. 2018;320(4):379-396. doi:
10.1001/jama.2018.8431PubMedGoogle ScholarCrossref 2.Canadian Task Force on the Periodic Health Examination. The periodic health examination.
Can Med Assoc J. 1979;121(9):1193-1254.
PubMedGoogle Scholar 4.Amstutz
A , Brown
JA , Ringera
I ,
et al. Engagement in care, viral suppression, drug resistance and reasons for non-engagement after home-based same-day ART initiation in Lesotho: a two-year follow-up of the CASCADE trial.
Clin Infec Dis. doi:
10.1093/cid/ciz1126 Published online November 29, 2019.
PubMedGoogle Scholar 5.Coffey
S , Bacchetti
P , Sachdev
D ,
et al. RAPID antiretroviral therapy: high virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population.
AIDS. 2019;33(5):825-832. doi:
10.1097/QAD.0000000000002124PubMedGoogle ScholarCrossref 6.Seybolt
L , Conner
K , Butler
I , VanSickels
N , Halperin
J . Rapid start lead to sustained viral suppression in young people in the South [Abstract 1073] in special issue: Abstracts From the 2020 Conference on Retroviruses and Opportunistic Infections.
Top Antivir Med. 2020;28(1):407.
Google Scholar 7.Cuzin
L , Cotte
L , Delpierre
C ,
et al; Dat’AIDS study group. Too fast to stay on track? shorter time to first anti-retroviral regimen is not associated with better retention in care in the French Dat’AIDS cohort.
PLoS One. 2019;14(9):e0222067. doi:
10.1371/journal.pone.0222067PubMedGoogle Scholar 8.Colasanti
J , Sumitani
J , Mehta
CC ,
et al. Implementation of a rapid entry program decreases time to viral suppression among vulnerable persons living with HIV in the Southern United States.
Open Forum Infect Dis. 2018;5(6):ofy104. doi:
10.1093/ofid/ofy104PubMedGoogle Scholar 10.Cahn
P , Madero
JS , Arribas
JR ,
et al; GEMINI study team. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Lancet. 2019;393(10167):143-155. doi:
10.1016/S0140-6736(18)32462-0PubMedGoogle ScholarCrossref 12.Zash
R . Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana. Poster presented at: 23rd International AIDS Conference; July 6-10, 2020; virtual.
13.Chinula
L , Brummel
SS , Ziemba
L ,
et al. Safety and efficacy of DTG vs EFV and TDF vs TAF in pregnancy: IMPAACT 2010 trial [Abstract 130] in special issue: Abstracts From the 2020 Conference on Retroviruses and Opportunistic Infections.
Top Antivir Med. 2020;28(1):42-43.
Google Scholar 14.Bakal
DR , Coelho
LE , Luz
PM ,
et al. Obesity following ART initiation is common and influenced by both traditional and HIV-/ART-specific risk factors.
J Antimicrob Chemother. 2018;73(8):2177-2185. doi:
10.1093/jac/dky145PubMedGoogle ScholarCrossref 15.Bares
SH , Smeaton
LM , Xu
A , Godfrey
C , McComsey
GA . HIV-infected women gain more weight than HIV-infected men following the initiation of antiretroviral therapy.
J Womens Health (Larchmt). 2018;27(9):1162-1169. doi:
10.1089/jwh.2017.6717PubMedGoogle ScholarCrossref 16.Sax
PE , Erlandson
KM , Lake
JE ,
et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials.
Clin Infect Dis. 2020;71(6):1379-1389. doi:
10.1093/cid/ciz999PubMedGoogle ScholarCrossref 17.Kouanfack
C , Mpoudi-Etame
M , Omgba Bassega
P ,
et al; NAMSAL ANRS 12313 study group. Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1.
N Engl J Med. 2019;381(9):816-826. doi:
10.1056/NEJMoa1904340PubMedGoogle ScholarCrossref 19.Bhagwat
P , Ofotokun
I , McComsey
GA ,
et al. Changes in waist circumference in HIV-infected individuals initiating a raltegravir or protease inhibitor regimen: effects of sex and race.
Open Forum Infect Dis. 2018;5(11):ofy201. doi:
10.1093/ofid/ofy201PubMedGoogle Scholar 20.Mayer
KH , Molina
JM , Thompson
MA ,
et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Lancet. 2020;396(10246):239-254. doi:
10.1016/S0140-6736(20)31065-5PubMedGoogle ScholarCrossref 21.Dooley
KE , Kaplan
R , Mwelase
N ,
et al; International Study of Patients with HIV on Rifampicin ING study group. Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial.
Clin Infect Dis. 2020;70(4):549-556.
PubMedGoogle Scholar 22.Cerrone
M , Alfarisi
O , Neary
M ,
et al. Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide.
J Antimicrob Chemother. 2019;74(6):1670-1678. doi:
10.1093/jac/dkz068PubMedGoogle Scholar 23.Dooley
KE , Savic
R , Gupte
A ,
et al; DOLPHIN study team. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial.
Lancet HIV. 2020;7(6):e401-e409. doi:
10.1016/S2352-3018(20)30032-1PubMedGoogle Scholar 24.Eron
JJ , Orkin
C , Cunningham
D ,
et al; EMERALD study group. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
Antiviral Res. 2019;170:104543. doi:
10.1016/j.antiviral.2019.104543PubMedGoogle Scholar 25.van Wyk
J , Ajana
F , Bisshop
F ,
et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose two-drug regimen versus continuing a tenofovir alafenamide-based three- or four-drug regimen for maintenance of virologic suppression in adults with HIV-1: phase 3, randomized, non-inferiority TANGO Study.
Clin Infect Dis. Published online January 6, 2020. doi:
10.1093/cid/ci1243Google Scholar 26.Aboud
M , Orkin
C , Podzamczer
D ,
et al. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
Lancet HIV. 2019;6(9):e576-e587. doi:
10.1016/S2352-3018(19)30149-3PubMedGoogle Scholar 27.Swindells
S , Andrade-Villanueva
JF , Richmond
GJ ,
et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression.
N Engl J Med. 2020;382(12):1112-1123. doi:
10.1056/NEJMoa1904398PubMedGoogle Scholar 28.Orkin
C , Arasteh
K , Górgolas Hernández-Mora
M ,
et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection.
N Engl J Med. 2020;382(12):1124-1135. doi:
10.1056/NEJMoa1909512PubMedGoogle Scholar 29.Overton
ET , Richmond
GJ , Rizzardini
G ,
et al. Cabotegravir + rilpivirine every 2 months is noninferior to monthly: ATLAS-2M STUDY [Abstract 34] in special issue: Abstracts From the 2020 Conference on Retroviruses and Opportunistic Infections.
Top Antivir Med. 2020;28(1):11.
Google Scholar 30.Olearo
F , Nguyen
H , Bonnet
F ,
et al. Impact of the M184V/I mutation on the efficacy of abacavir/lamivudine/dolutegravir therapy in HIV treatment-experienced patients.
Open Forum Infect Dis. 2019;6(10):ofz330. doi:
10.1093/ofid/ofz330PubMedGoogle Scholar 31.Andreatta
K , Willkom
M , Martin
R ,
et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
J Antimicrob Chemother. 2019;74(12):3555-3564. doi:
10.1093/jac/dkz347PubMedGoogle Scholar 32.Acosta
RK , Willkom
M , Martin
R ,
et al. Resistance analysis of bictegravir-emtricitabine-tenofovir alafenamide in HIV-1 treatment-naive patients through 48 weeks.
Antimicrob Agents Chemother. 2019;63(5):1-3. doi:
10.1128/AAC.02533-18PubMedGoogle Scholar 33.Althoff
KN , Gebo
KA , Moore
RD ,
et al; North American AIDS Cohort Collaboration on Research and Design. Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies.
Lancet HIV. 2019;6(2):e93-e104. doi:
10.1016/S2352-3018(18)30295-9PubMedGoogle Scholar 34.Surial
B , Ledergerber
B , Calmy
A ,
et al; Swiss HIV Cohort study. Changes in renal function after switching from TDF to TAF in HIV-infected individuals: a prospective cohort study.
J Infect Dis. 2020;222(4):637-645. doi:
10.1093/infdis/jiaa125PubMedGoogle Scholar 35.Hoy
JF , Richardson
R , Ebeling
PR ,
et al; ZEST study investigators. Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV.
AIDS. 2018;32(14):1967-1975.
PubMedGoogle Scholar 36.Schafer
JJ , Sassa
KN , O’Connor
JR , Shimada
A , Keith
SW , DeSimone
JA . Changes in body mass index and atherosclerotic disease risk score after switching from tenofovir disoproxil fumarate to tenofovir alafenamide.
Open Forum Infect Dis. 2019;6(10):ofz414. doi:
10.1093/ofid/ofz414PubMedGoogle Scholar 37.Mallon
P , Brunet
L , Hsu
R , Fusco
J , Mounzer
K , Prajapati
G . Weight gain before and after switch from TDF to TAF. Poster presented at: 23rd International AIDS Conference; July 6-10, 2020; virtual.
38.Bajema
KL , Nance
RM , Delaney
JAC ,
et al. Changing rates of heavily treatment experienced persons with HIV in the United States, 2000-2017. Poster presented at: 10th IAS Conference on HIV Science; July 21-24, 2019; Mexico City, Mexico.
39.Aboud
M , Kaplan
R , Lombaard
J ,
et al. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.
Lancet Infect Dis. 2019;19:253-264.
Google Scholar 40.Gandhi
RT , Tashima
KT , Smeaton
LM ,
et al. Long-term outcomes in a large randomized trial of HIV-1 salvage therapy: 96-week results of AIDS Clinical Trials Group A5241 (OPTIONS).
J Infect Dis. 2020;221(9):1407-1415. doi:
10.1093/infdis/jiz281PubMedGoogle Scholar 42.Emu
B , DeJesus
E , Berhe
M ,
et al. Ibalizumab efficacy and safety through 48 weeks of treatment: results of an expanded access protocol (TMB-311).
Cre Open Forum Infect Dis. 2020;6(suppl 2):S303. doi:
10.1093/ofid/ofz360.729Google Scholar 43.Millham
LRI , Scott
JA , Sax
PE ,
et al. Clinical and economic impact of ibalizumab for people with multidrug-resistant HIV in the United States.
J Acquir Immune Defic Syndr. 2020;83(2):148-156. doi:
10.1097/QAI.0000000000002241PubMedGoogle Scholar 45.Soulie
C , Santoro
MM , Storto
A ,
et al. Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
J Antimicrob Chemother. 2020;75(4):1026-1030. doi:
10.1093/jac/dkz553PubMedGoogle Scholar 49.DiNenno
EA , Prejean
J , Delaney
KP ,
et al. Evaluating the evidence for more frequent than annual HIV screening of gay, bisexual, and other men who have sex with men in the United States: results from a systematic review and CDC expert consultation.
Public Health Rep. 2018;133(1):3-21. doi:
10.1177/0033354917738769PubMedGoogle Scholar 50.Manak
MM , Jagodzinski
LL , Shutt
A ,
et al; RV254/SEARCH010 and the RV217 study teams. Decreased seroreactivity in individuals initiating antiretroviral therapy during acute HIV infection.
J Clin Microbiol. 2019;57(10):e00757-e19. doi:
10.1128/JCM.00757-19PubMedGoogle Scholar 51.Pereira
IO , Pascom
A , Mosimann
G ,
et al. Post-exposure prophylaxis following consented sexual exposure: impact of national recommendations on user profile, drug regimens and estimates of averted HIV infections.
HIV Med. 2020;21(4):240-245. doi:
10.1111/hiv.12825PubMedGoogle Scholar 52.Alghamdi
A , Hempel
A , Heendeniya
A , Clifford-Rashotte
M , Tan
DHS , Bogoch
II . HIV post-exposure prophylaxis-in-pocket (“PIP”): long-term follow-up of individuals with low-frequency, high-risk HIV exposures.
AIDS. doi:
10.1097/QAD.0000000000002441 Published online November 14, 2019.
PubMedGoogle Scholar 53.Hyle
EP , Scott
JA , Sax
PE ,
et al. Clinical impact and cost-effectiveness of genotype testing at human immunodeficiency virus diagnosis in the United States.
Clin Infect Dis. 2020;70(7):1353-1363. doi:
10.1093/cid/ciz372PubMedGoogle Scholar 54.Alvarez
M , Casas
P , de Salazar
A ,
et al; CoRIS. Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice.
J Antimicrob Chemother. 2019;74(6):1693-1700. doi:
10.1093/jac/dkz067PubMedGoogle Scholar 55.Günthard
HF , Calvez
V , Paredes
R ,
et al. Human immunodeficiency virus drug resistance: 2018 recommendations of the International Antiviral Society-USA Panel.
Clin Infect Dis. 2019;68(2):177-187. doi:
10.1093/cid/ciy463PubMedGoogle Scholar 56.Zhu
J , Rozada
I , David
J ,
et al. The potential impact of initiating antiretroviral therapy with integrase inhibitors on HIV transmission risk in British Columbia, Canada.
EClinicalMedicine. 2019;13:101-111. doi:
10.1016/j.eclinm.2019.07.001PubMedGoogle Scholar 57.Liu
CM , Prodger
J , Tobian
A ,
et al. Abundance of penile anaerobes, IL-8, and the risk of HIV acquisition, Rakai, Uganda [Abstract 87] in special issue: Abstracts From the 2017 Conference on Retroviruses and Opportunistic Infections.
Top Antivir Med. 2017;27(suppl 1):35s.
Google Scholar 60.Grulich
AE , Guy
R , Amin
J ,
et al; Expanded PrEP Implementation in Communities New South Wales (EPIC-NSW) research group. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.
Lancet HIV. 2018;5(11):e629-e637. doi:
10.1016/S2352-3018(18)30215-7PubMedGoogle Scholar 62.Landovitz
RJ , Donnell
D , Clement
M ,
et al. HPTN 083 interim results: pre-exposure prophylaxis containing long-acting injectable cabotegravir is safe and highly effective for cisgender men and transgender women who have sex with men. Poster presented at: 23rd International AIDS Conference; July 6-10, 2020; virtual.
63.Krakower
D . Impact of COVID-19 on HIV pre-exposure prophylaxis care at a Boston community health center. Poster presented at: 23rd International AIDS Conference; July 6-10, 2020; virtual.
64.Cardo
DM , Culver
DH , Ciesielski
CA ,
et al; Centers for Disease Control and Prevention Needlestick Surveillance Group. A case-control study of HIV seroconversion in health care workers after percutaneous exposure.
N Engl J Med. 1997;337(21):1485-1490.
Google Scholar 70.Autenrieth
CS , Beck
EJ , Stelzle
D , Mallouris
C , Mahy
M , Ghys
P . Global and regional trends of people living with HIV aged 50 and over: estimates and projections for 2000-2020.
PLoS One. 2018;13(11):e0207005. doi:
10.1371/journal.pone.0207005PubMedGoogle Scholar 71.Marcus
JL , Leyden
WA , Alexeeff
SE ,
et al. Comparison of overall and comorbidity-free life expectancy between insured adults with and without HIV infection, 2000-2016.
JAMA Netw Open. 2020;3(6):e207954.
Google Scholar 72.Blanco
JR , Jarrín
I , Vallejo
M ,
et al; CoRIS. Definition of advanced age in HIV infection: looking for an age cut-off.
AIDS Res Hum Retroviruses. 2012;28(9):1000-1006. doi:
10.1089/aid.2011.0377PubMedGoogle Scholar 73.Guaraldi
G , Malagoli
A , Calcagno
A ,
et al. The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65-74 years and more than 75 years.
BMC Geriatr. 2018;18(1):99. doi:
10.1186/s12877-018-0789-0PubMedGoogle Scholar 74.Courlet
P , Stader
F , Guidi
M ,
et al; Swiss HIV Cohort Study. Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
AIDS. 2020;34(1):103-108. doi:
10.1097/QAD.0000000000002372PubMedGoogle Scholar 76.Verheij
E , Kirk
GD , Wit
FW ,
et al; AGEhIV Cohort. Frailty is associated with mortality and incident comorbidity among middle-aged human immunodeficiency virus (HIV)-positive and HIV-negative participants.
J Infect Dis. 2020;222(6):919-928. doi:
10.1093/infdis/jiaa010PubMedGoogle Scholar 79.Hosaka
KRJ , Greene
M , Premeaux
TA ,
et al. Geriatric syndromes in older adults living with HIV and cognitive impairment.
J Am Geriatr Soc. 2019;67(9):1913-1916. doi:
10.1111/jgs.16034PubMedGoogle Scholar 81.Pritchard
JM , Kennedy
CC , Karampatos
S ,
et al. Measuring frailty in clinical practice: a comparison of physical frailty assessment methods in a geriatric out-patient clinic.
BMC Geriatr. 2017;17(1):264. doi:
10.1186/s12877-017-0623-0PubMedGoogle Scholar 82.Makinson
A , Dubois
J , Eymard-Duvernay
S ,
et al. Increased prevalence of neurocognitive impairment in aging people living with human immunodeficiency virus: the ANRS EP58 HAND 55-70 study.
Clin Infect Dis. 2020;70(12):2641-2648. doi:
10.1093/cid/ciz670PubMedGoogle Scholar 83.Harris
M , Brouillette
MJ , Mayo
N ,
et al. Associations of loneliness with cognitive function and quality of life (QoL) among older HIV+ adults. Presented at: 9th International Workshop on HIV and Aging; September 13-14, 2018; New York, NY.
84.Greysen
SR , Horwitz
LI , Covinsky
KE , Gordon
K , Ohl
ME , Justice
AC . Does social isolation predict hospitalization and mortality among HIV+ and uninfected older veterans?
J Am Geriatr Soc. 2013;61(9):1456-1463. doi:
10.1111/jgs.12410PubMedGoogle Scholar 85.Nguyen
A , Seal
D . Effect of social networks on purpose in life, depression, and physical function among older adults living with HIV. Poster presented at: American Public Health Association Annual Meeting and Expo; November 2-6, 2019; Philadelphia, PA.
86.Logie
CH , Wang
Y , Lacombe-Duncan
A ,
et al. HIV-related stigma, racial discrimination, and gender discrimination: pathways to physical and mental health-related quality of life among a national cohort of women living with HIV.
Prev Med. 2018;107:36-44. doi:
10.1016/j.ypmed.2017.12.018PubMedGoogle Scholar 89.Roberts
DA , Tan
N , Limaye
N , Irungu
E , Barnabas
RV . Cost of differentiated HIV antiretroviral therapy delivery strategies in Sub-Saharan Africa: a systematic review.
J Acquir Immune Defic Syndr. 2019;82(suppl 3):S339-S347. doi:
10.1097/QAI.0000000000002195PubMedGoogle Scholar 90.Beer
L , Tie
Y , Weiser
J , Shouse
RL . Nonadherence to any prescribed medication due to costs among adults with HIV infection—United States, 2016-2017.
MMWR Morb Mortal Wkly Rep. 2019;68(49):1129-1133. doi:
10.15585/mmwr.mm6849a1PubMedGoogle Scholar 94.Havlir
D , Lockman
S , Ayles
H ,
et al; (Universal Test, Treat Trials) UT3 Consortium. What do the Universal Test and Treat trials tell us about the path to HIV epidemic control?
J Int AIDS Soc. 2020;23(2):e25455. doi:
10.1002/jia2.25455PubMedGoogle Scholar